CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 329 enrolled
Drug / intervention
Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05397730
NCT05397730N/ACompleted

Levels of Mycobacterium Tuberculosis Cell-free DNA (MTB cfDNA) in Tuberculous and Non-tuberculous Pleural Effusion

Chinese University of Hong Kong·observational·Posted May 31, 2022·Updated Mar 30, 2026

In Brief

An observational study evaluating Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA) for Tuberculosis, Pleural. Completed, enrolled 329 participants across 1 site.

Detailed Summary

Tuberculous pleuritis (TBP) is the most common manifestation of extrapulmonary TB. Its diagnosis is challenging due to the low sensitivity of mycobacterial culture from the pleural fluid and the need for invasive pleural biopsy. Preliminary data has shown the superior sensitivity of Mycobacterium tuberculosis cell-free DNA (MTB cfDNA) to conventional culture and MTB polymerase chain reaction (PCR), but the cutoff level of MTB cfDNA was not determined. This study involves a prospective collection of pleural fluid due to TBP and non-TBP aetiologies, with subsequent testing by MTB culture, MTB cfDNA and MTB PCR. The levels of MTB cfDNA in the pleural fluid will be correlated with different types of diagnosis, and its diagnostic accuracy will be compared with conventional culture and MTB PCR. A confirmatory study result of MTB cfDNA can shorten the time to diagnosis, reduce the need for pleural biopsy and prevent the delay of definitive treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesHong Kong
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedMay 31, 2022
Enrollment StartSep 1, 2022
Primary CompletionMar 31, 2024
Study CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.1 years ago

Interventions

Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA)other

Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis